331
Participants
Start Date
August 4, 2022
Primary Completion Date
June 22, 2023
Study Completion Date
June 22, 2023
Ripasudil
K-321 ophthalmic solution
Placebo
Placebo ophthalmic solution
NYU Grossman School of Medicine, New York
Seeta Eye Center, Poughkeepsie
Eye Care Specialists, Kingston
Clayton Eye Clinical Research, LLC, Morrow
Levenson Eye Associates, Jacksonville
International Research Center, Tampa
Eye Associates of Fort Myers, Fort Myers
Eye Care Institute/Butchertown Clinical Trials, Louisville
Cincinnati Eye Institute, Mason
Cincinnati Eye Institute, Cincinnati
Fraser Eye Care Center, Fraser
Vance Thompson Vision, Sioux Falls
Vance Thompson Vision ND, West Fargo
Vance Thompson Vision-MT, Bozeman
Comprehensive Eye Care, Ltd., Washington
Tekwani Vision Center, St Louis
Ophthalmology Associates, St Louis
Ophthalmology Consultantants, Ltd., St Louis
Silverstein Eye Centers, Kansas City
Durrie Vision, Overland Park
Vance Thompson Vision- NE, Omaha
Houston Eye Associates, Houston
Terry Eye Associates, San Antonio
DCT-Shah Research, LLC dba Discovery Clinical Trials, Mission
Hill Country Eye Center, Cedar Park
Lake Travis Eye & Laser Center, Lakeway
Keystone Research, Austin
Louis M. Alpern, M.D., M.P.H.,P.A., El Paso
Icon Eye Care, Grand Junction
Cornea and Cataract Consultants of Arizona, Phoenix
Schwartz Laser Eye Center, Scottsdale
Wellish Vision Institute, Las Vegas
Center for Sight, Las Vegas
United Medical Research Institute, Inglewood
Premiere Practice Management, LLC, Torrance
Wolstan and Goldberg Eye Associates, Torrance
SoCal Eye Physicians and Associates, Long Beach
Alvarado Eye Associates, La Mesa
Pendleton Eye Center, Oceanside
Inland Eye Specialists, Hemet
Visionary Research Institute, Newport Beach
North Bay Eye Associates, Petaluma
Martel Eye Medical Group, Rancho Cordova
Maine Eye Center, Portland
Centro Oftalmologico Metropolitano, San Juan
Lead Sponsor
Kowa Research Institute, Inc.
INDUSTRY